StockTipsArenaBeta

BUY Dr. Lal Path Labs Ltd. — Citigroup

BUYDr. Lal Path Labs Ltd.
Dr. Lal Path Labs share price target & all analyst calls

byCitigroupHorizon: NA (inferred 1 year)9 Jul 2026via NDTV Profit (Live)

Entry₹1,674.5Inferred
Target₹1,950
Total upside +16.45% (call closed)
Stop lossNot given
Exit₹1,9504 Aug 2026, 12:08 pm
Target hit+16.45%0.00%upside left
Follow Citigroup for new calls(100% target hit, 52 closed calls)Get alertsWatch LALPATHLAB for new buy/sell callsGet alertsSee 3 active Long-term calls on LALPATHLABSee 274 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 4 Aug 2026
10 supporting2 neutral0 opposing
Supports the BUY call (10)

2 advisors have active short-term BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·30 Jul · 4d ago

Dr Lal Path Labs shares soar 8% after Q1 earnings beat estimates. What Nomura, Nuvama, other brokerages are saying?

NewsEt-Markets·27 Jul · 1w ago

(opens in new tab)

1 other SEBI-registered advisor has an active long-term BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·27 Jul · 1w ago

Dr. Lal PathLabs reported Q1 FY27 results with revenue up 19.1% to Rs 798 Cr. EBITDA increased 28.7% to Rs 247 Cr. PAT was Rs 170 Cr. The company also announced an interim dividend of 50% (Rs 5/share)

BSE · Company Update·24 Jul · 1w ago

(opens in new tab)

Dr. Lal Path Labs Ltd. announced its Q1 FY27 financial results, reporting a revenue of Rs 798 Cr, a 19.1% increase year-on-year. EBITDA grew by 28.7% to Rs 247 Cr, and PAT increased by 27.2% to Rs 170

NSE · Press Release·24 Jul · 1w ago

(opens in new tab)
Neutral / worth noting (2)

The Board of Directors approved un-audited financial results for Q1 FY27, declared an interim dividend of INR 5 per share, and approved the grant of stock options. Additionally, the company approved a

BSE · Company Update·24 Jul · 1w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Lal Path Labs

All analyst calls on Dr. Lal Path Labs

More from Citigroup

Every call and its outcome